Clinical Pipeline - B2 Receptor Antagonism
Deucrictibant is the only oral bradykinin B2-receptor antagonist currently in clinical development, to our knowledge.
Pharvaris has a platform of novel, potent, and selective B2 receptor antagonist small molecules for the treatment of bradykinin-mediated diseases.
On-Demand
Prophylaxis
Treatment Strategy
During the shared decision process, people living with HAE and their treating physicians, may opt for treatment of attacks (on-demand treatment) or may prefer to prevent attacks (prophylactic treatment) based on clinical assessment and personal choice.
By bringing the promise of both these new treatment options to people living with HAE, Pharvaris aims to enable those with HAE to have fewer disruptions in their daily activities, resulting in an improved quality of life.
Product Summary
PHVS416 (deucrictibant immediate-release capsule)
- Rapid absorption11
Rapidly reaches therapeutic exposure within 15-20 minutes,12 making it optimal for on-demand oral treatment of HAE attacks.
PHVS719 (deucrictibant extended-release tablet)
- Sustained absorption9
Maintains sustained therapeutic exposure over 24 hours10 from day one, allowing for once-daily oral treatment to prevent HAE attacks.
Deucrictibant
Deucrictibant is the only oral B2 receptor antagonist currently in clinical development. We aim to develop distinct, optimized formulations for both the on-demand treatment, through rapid onset of activity, and prophylactic treatment, through prolonged therapeutic activity, of HAE.
